This site is intended for health professionals only
Thursday 19 October 2017
Share |

New data on Bayer’s Xarelto®

Related articles

HAEMATOLOGY AND ONCOLOGY
HAEMATOLOGY AND ONCOLOGY
HAEMATOLOGY AND ONCOLOGY
HAEMATOLOGY AND ONCOLOGY
HAEMATOLOGY AND ONCOLOGY
LATEST NEWS
Bayer HealthCare announced that new data from the clinical development programme for its oral anticoagulant Xarelto® (rivaroxaban) will be presented at the 54th American Society of Haematology (ASH) Annual Meeting and Exposition in Atlanta, GA, USA, December 8-11, 2012. These data underscore the benefits of rivaroxaban for patients at risk of dangerous blood clots across multiple venous thromboembolic conditions.
Notable data analyses to be presented at ASH 2012 include:

Ads by Google